Drug search by name

Foscavir and Hematologic toxicities

Result of checking the interaction of drug Foscavir and disease Hematologic toxicities for safety when used together.

Check result:

Foscavir <> Hematologic toxicities

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

The use of foscarnet is associated with hematologic toxicities, most commonly anemia and granulocytopenia. Thrombocytopenia has been reported rarely. Therapy with foscarnet should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression. Routine blood counts are recommended.

References:

Jacobson MA "Review of the toxicities of foscarnet." J Acquir Immune Defic Syndr 5 (1992): s11-7
Willocks L, Brettle R "Foscarnet and pancytopenia." J Antimicrob Chemother 29 (1992): 232
"Product Information. Foscavir (foscarnet)." Astra USA, Westborough, MA.
Palestine AG, Polis MA, De Smet MD, et al "A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS." Ann Intern Med 115 (1991): 665-73
Ringden O, Lonnqvist B, Paulin T, et al "Pharmacokinetics, safety and preliminary clinical experiences using foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients." J Antimicrob Chemother 17 (1986): 373-87
Chrisp P, Clissold SP "Foscarnet: a review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis." Drugs 41 (1991): 104-29

Foscavir

Generic Name: foscarnet

Brand Name: Foscavir

Synonyms: n.a.

What is Foscavir?